---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-002490"
form_type: "8-K"
ticker: "IRWD"
cik: "0001446847"
company_name: "IRONWOOD PHARMACEUTICALS INC"
filed_at: "2022-01-10T23:59:59+00:00"
generated_at: "2026-06-27T19:19:38.026284+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Ironwood expects LINZESS to exceed $1B in 2021 US net sales; raises 2021 adjusted EBITDA guidance to >$230M

## Summary
- LINZESS U.S. net sales expected to surpass $1B in 2021, achieving blockbuster status.
- 2021 guidance updated: LINZESS growth at high end of 6-8%; total revenue high end of $390-410M.
- Adjusted EBITDA guidance raised to >$230M (from >$210M) for 2021.
- 2022 guidance: LINZESS low single-digit growth; total revenue $420-430M; adjusted EBITDA >$250M.
- Board authorized $150M share repurchase; $27M repurchased in Q4 2021.

## SEC filing metadata
- accession: 0001104659-22-002490
- form_type: 8-K
- ticker: IRWD
- cik: 0001446847
- company_name: IRONWOOD PHARMACEUTICALS INC
- filed_at: 2022-01-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446847/000110465922002490/0001104659-22-002490-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446847/000110465922002490/tm222198d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-002490
- JSON: https://secwatch.observer/filing/0001104659-22-002490.json
- Plain text: https://secwatch.observer/filing/0001104659-22-002490.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.